MedTrace Logo

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

NCT06387628 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-08-02

No results posted yet for this study

Summary

To evaluate the efficacy and safety of LM108 plus toripalimab plusnab-paclitaxel or eribulin as first-line or post-line treatment in patients with metastatic triple-negative breast cancer.

Conditions

  • TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

LM-108

LM-108, 10mg/kg, d1, q6w

DRUG

Toripalimab

Toripalimab, 240 mg, d1, q3w

DRUG

Eribulin

Eribulin 1.4 mg/m2, d1, 8 , q3w

DRUG

Nab paclitaxel

Nab paclitaxel 125 mg/m2, d1, 8 , q3w

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-10
Primary Completion
2026-04-01
Completion
2027-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06387628 on ClinicalTrials.gov